
Keywords: ADT; Androgen deprivation therapy; AR; Androgen receptor; CRPC; Castration resistant prostate cancer; DHT; Dihydrotestosterone; EGF; Epidermal growth factor; EMT; Epithelial mesenchymal transition; ERβ; Estrogen receptor β; FGF; Fibroblast growth factor